Q-omics provides the consensus-scored RNF139 profile across patient tissues and cancer cell-line models. RNF139 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNF139 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RNF139 RNA expression shows 18,790 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where RNF139 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF139 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF139 survival associations across molecular data types. RNF139 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF139 RNA expression–survival associations across cancer types. High RNF139 expression shows unfavorable associations in UVM, CESC, SCLC and KIRP, but favorable associations in LGG and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RNF139 RNA expression.
This table summarizes RNF139 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RNF139. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF139 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRP, KIRC, LIHC and BRCA. The HNSC box plot shows higher RNF139 RNA expression in tumor versus normal tissue (log2 FC = +1.126, t-test p < 0.001).
This table shows molecular features associated with RNF139 in patient tissues and cancer cell lines. In patient samples, RNF139 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF139 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
